126 related articles for article (PubMed ID: 16144501)
1. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.
Benedict A; Brown RE
Expert Opin Pharmacother; 2005 Sep; 6(11):1789-801. PubMed ID: 16144501
[TBL] [Abstract][Full Text] [Related]
2. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.
John-Baptiste AA; Wu W; Rochon P; Anderson GM; Bell CM
PLoS One; 2013; 8(5):e62614. PubMed ID: 23671612
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.
Lindgren P; Jönsson B; Redaelli A; Radice D
Pharmacoeconomics; 2002; 20(2):101-8. PubMed ID: 11888362
[TBL] [Abstract][Full Text] [Related]
5. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Dranitsaris G; Verma S; Trudeau M
Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
[TBL] [Abstract][Full Text] [Related]
6. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Karnon J; Jones T
Pharmacoeconomics; 2003; 21(7):513-25. PubMed ID: 12696991
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Moeremans K; Annemans L
Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
[TBL] [Abstract][Full Text] [Related]
10. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
11. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole data show continued delay in relapse, but no clear survival advantage.
Travis K
J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
[No Abstract] [Full Text] [Related]
15. Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Frederix GW; Severens JL; Hövels AM; Raaijmakers JA; Schellens JH
Value Health; 2012 Jan; 15(1):94-105. PubMed ID: 22264977
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Verma S; Rocchi A
Support Care Cancer; 2003 Nov; 11(11):728-34. PubMed ID: 12883965
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention in breast cancer.
Vogel V
Clin Adv Hematol Oncol; 2005 Jul; 3(7):531-3. PubMed ID: 16167032
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
20. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
